Experts identify sex and gender differences in cognitive resistance and resilience to Alzheimer’s disease

Io­n­is Phar­ma­ceu­ti­cals’ hered­i­tary an­gioede­ma treat­ment helped cut the rate of at­tacks as­so­ci­at­ed with the rare ge­net­ic dis­ease in a Phase III study. Peo­ple with hered­i­tary

Ab­b­Vie will end the last parts of its CD47 agree­ment with I-Mab, the Mary­land and Shang­hai biotech dis­closed in a Fri­day SEC fil­ing. The Chica­go-area